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Abstract
Predicting long-term stroke mortality is a clinically important and unmet need. We aimed to develop and internally validate a 
10-year ischaemic stroke mortality prediction score. In this UK cohort study, 10,366 patients with first-ever ischaemic stroke 
between January 2003 and December 2016 were followed up for a median (interquartile range) of 5.47 (2.96–9.15) years. 
A Cox proportional-hazards model was used to predict 10-year post-admission mortality. The predictors associated with 
10-year mortality included age, sex, Oxfordshire Community Stroke Project classification, estimated glomerular filtration 
rate (eGFR), pre-stroke modified Rankin Score, admission haemoglobin, sodium, white blood cell count and comorbidities 
(atrial fibrillation, coronary heart disease, heart failure, cancer, hypertension, chronic obstructive pulmonary disease, liver 
disease and peripheral vascular disease). The model was internally validated using bootstrap resampling to assess optimism 
in discrimination and calibration. A nomogram was created to facilitate application of the score at the point of care. Mean age 
(SD) was 78.5 ± 10.9 years, 52% female. Most strokes were partial anterior circulation syndromes (38%). 10-year mortality 
predictors were: total anterior circulation stroke (hazard ratio, 95% confidence intervals) (2.87, 2.62–3.14), eGFR < 15 (1.97, 
1.55–2.52), 1-year increment in age (1.04, 1.04–1.05), liver disease (1.50, 1.20–1.87), peripheral vascular disease (1.39, 
1.23–1.57), cancers (1.37, 1.27–1.47), heart failure (1.24, 1.15–1.34), 1-point increment in pre-stroke mRS (1.20, 1.17–1.22), 
atrial fibrillation (1.17, 1.10–1.24), coronary heart disease (1.09, 1.02–1.16), chronic obstructive pulmonary disease (1.13, 
1.03–1.25) and hypertension (0.77, 0.72–0.82). Upon internal validation, the optimism-adjusted c-statistic was 0.76 and 
calibration slope was 0.98. Our 10-year mortality model uses routinely collected point-of-care information. It is the first 
10-year mortality score in stroke. While the model was internally validated, further external validation is also warranted.
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Introduction
Despite prevention, treatment advances and extensive 
research, stroke continues to pose a significant global 
health burden. It causes significant societal and economic 
hardship, with stroke costs representing 3–4% of total 
health care expenditures in Western countries [1]. It is the 
second leading cause of death worldwide [2]. Similarly, in 
the UK, cerebrovascular accidents are the third commonest 
cause of death [3].
Clinical prediction scores provide clinicians, patients 
and their families with information that can facilitate deci-
sions about their care, identifying those at high risk who 
require immediate intervention. They also provide very 
important information on patient prognosis. Numerous 
attempts have been made to create a reliable, clinically 
useful and easy-to-use stroke prediction score. Outcomes 
considered in previously developed scores include in-
hospital, 3 months, 6 months, 1-year mortality, stroke 
recurrence as well as functional outcomes: mRS (modi-
fied Rankin Score) and hospital length of stay [4–6]. 
None of the existing scores is widely used in clinical 
practice. Some of the potential reasons for that can be a 
very complex scoring system, included variables that are 
not routinely collected, or imaging results required, that 
may not be available in some settings. In recent years, life 
expectancy of stroke survivors has been increasing—from 
1983 to 1994, it increased by 22.9% for men and 12.9% for 
women [7]. Therefore, a prediction model for mortality in 
the longer term (10 years) is needed to guide long-term 
prognosis and can be used as prognosis tool to stratify 
patients participating in clinical studies. Whilst many 
stroke scores provide clinicians with short-term mortality 
and disability prognosis, so far none of them can predict 
10-year mortality.
In the current study, we aimed to develop and internally 
validate a score using readily available clinical informa-




In this prospective cohort study, we included participants 
from the Norfolk and Norwich Stroke and TIA Regis-
ter (NNSTR) [8] database which includes consecutive 
stroke admissions to the Norfolk and Norwich Univer-
sity Hospitals, a large tertiary centre in England covering 
an area with a catchment population of 790,000 in 2003 
and 876,000 in 2016 [9]. Ethical approval was obtained 
from the Newcastle and Tyneside National Health Service 
Research Ethics Committee (17/NE/0277) as a research 
database, which does not require individual patient con-
sent. The protocol of our study was approved by the steer-
ing committee of the NNSTR. Selection criteria as well 
as data collection methods have been described previ-
ously [8]. All patients in the current study were admitted 
between January 2003 and December 2016, and followed 
up until June 2017. The data for this study are available 
from the corresponding author upon reasonable request.
Predictors
Candidate predictors were chosen based on the literature. 
This was followed by a manual backward elimination pro-
cess which excluded candidate predictors which did not 
exhibit a statistically significant relationship with the log 
hazard of mortality, as described in detail below in the 
‘Cox proportional-hazards model’ section. Candidate pre-
dictors included in the elimination process were age [10], 
sex [10], pre-stroke disability (measured using the modi-
fied Rankin Score), type of stroke [11], haemoglobin [12], 
sodium [13], white blood cell count [14], as well as major 
comorbidities such as ischaemic heart disease [10], atrial 
fibrillation [9], cancers [15], hypertension [16], chronic 
obstructive pulmonary disease [17], liver disease [18], 
peripheral vascular disease [19], heart failure [20, 21] and 
diabetes [10] eGFR [22]. The candidate predictors were 
measured on admission unless specified otherwise. The 
indicator of renal function in our model, eGFR, was calcu-
lated using the imputed creatinine values and the Chronic 
Kidney Disease Epidemiology Collaboration formula [23]. 
Pre-existing co-morbidity status on admission was identi-
fied from International Classification of Diseases-Tenth 
Revision codes based on clinical findings and retrieved 
from the hospital administration database (Supplementary 
Table 1 in the online-only Data Supplement). Continuous 
predictors that were found not to have a normal distribu-
tion (white blood cell count and sodium) were winsorized 
to the 99th percentile to reduce the influence of extreme 
outliers on the results.
Outcome
The outcome of interest was all-cause mortality within the 
10 years after ischaemic stroke. Discharge status (alive or 
deceased) was recorded in the hospital. Mortality informa-
tion after discharge was obtained by record linkage with 
the Office of National Statistics database which captures all 
deaths in the UK.
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Handling of missing data
We performed a logistic regression (Supplementary Table 8) 
to explore the differences between patients with missing data 
and those without any missing data.
All predictors with missingness under 15% were consid-
ered in the initial model.
It has been recommended that the number of imputed 
datasets should be equal or higher than the percentage of 
cases with at least one missing variable. Based on the pro-
portion of cases with at least one variable with missing data 
[24] we imputed 20 datasets. Based on the characteristics of 
the patients with missing data and those without, the data 
were deemed to be likely to be missing at random [24]. A 
multiple imputation by chained equations algorithm with 20 
imputed datasets was thus implemented in R version 3.6.3 
(R package mice [25]) using a predictive mean matching 
algorithm drawing from five nearest neighbours. Coronary 
heart disease, diabetes, congestive heart failure, chronic kid-
ney disease, atrial fibrillation, cancers, dementia, COPD, 
liver disease, hyperlipidaemia, PVD, age, sex and the Nel-
son–Aalen cumulative hazard were included as predictors.
Statistical analysis
Data were analysed using R version 3.6.3 (R Foundation 
for Statistical Computing, Vienna, Austria) and Stata 15.1 
SE (StataCorp 2017, Stata Statistical Software: Release 15, 
College Station, TX: StataCorp LLC). The R rms pack-
age [26] was employed to internally validate the score and 
create the nomogram, whilst the hmisc package [27] was 
employed to perform the Cox proportional-hazards model. 
The median follow-up time was calculated using the reverse 
Kaplan–Meier method [28].
Cox proportional‑hazards model
A Cox proportional hazards model was used to obtain 
regression coefficients. All the candidate predictors were 
added and then through a manual backward elimination 
process the non-significant predictors were removed. Only 
significant predictors were included in the final model 
(p < 0.05). Given that blood measurement data (haemo-
globin, white blood count, and sodium) may not exhibit 
a linear relationship with the outcome, these predictors 
were added to the model as restricted cubic splines (RCS) 
if this parametrisation was found to improve model fit. The 
transformation that resulted in the model with the lowest 
Akaike Information Criterion (AIC) was chosen for each 
predictor. Stroke type (OCSP classification), pre-stroke 
modified Rankin score and estimated glomerular filtra-
tion rate (eGFR) were included as categorical variables. 
The eGFR was calculated using the imputed creatinine 
values and categorised as: > 90, 60–90, 45–60, 30–45, 
15–30, <  = 15 (> 90 as the reference category), given the 
previously described predictive inaccuracy of eGFR at val-
ues > 90 [29]. For stroke type, the designated reference 
category was LACS.
Nomogram development
The prediction model was developed and validated was 
then converted into a nomogram to allow clinicians to eas-
ily calculate the predicted probability of 10-year mortality 
in stroke patients. The nomogram was created based on the 
coefficients of the Cox proportional-hazards model. Each 
predictor value is represented on a separate axis and the 
amount of corresponding points is noted from the ‘Points’ 
axis. The total of the points from all predictors (Total Point 
axis) then maps to a predicted 10-year mortality at the bot-
tom of the nomogram (10-year Mortality axis).
Internal validation
Nagelkerke’s R2 was used to measure the proportion of vari-
ation of the outcome that can be explained by the regression 
model and predictors [30]. To assess the ability of the model 
to discriminate between patients at high and low risk of mor-
tality, we used Harrell’s C-statistic. We internally validated 
the prediction model using 500 bootstrapped samples from 
the dataset to obtain optimism-adjusted c-statistic and cali-
bration slope. This method involves generating samples of 
the same size as the original dataset with replacement [26]. 
New final models were developed in each of the bootstrap 
samples and their performance (C-statistic and calibration 
curve) was assessed (bootstrap performance). Each of the 
models was then applied to the original dataset and the same 
performance was assessed (test performance). The average 
difference in the bootstrap and test performance is the ‘opti-
mism’ in performance of the original model. Optimism-
adjusted performance is estimated as performance in the 
original dataset minus the ‘optimism’. This is an estimate of 
internal validity, reflecting validation for the underlying pop-
ulation where the data originated from. Hazard regression 
was used to estimate the relationship between the predicted 
survival probability at 10 years and the observed outcomes 
to derive a calibration curve [31, 32]. The bootstrap process 
de-biased the estimates to correct for overfitting. The cali-
bration slope represents the gradient of a linear calibration 
curve. Its value indicates whether the model is overfitting 
(slope < 1) or underfitting (slope > 1). For easier visualisa-
tion of the score performance, we also plotted Kaplan–Meier 
curves by score quintiles and a histogram of the total points’ 
distribution across the study sample.
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Data availability
The data underlying this study are available from the cor-
responding author upon reasonable request.
Results
Patient population
A total of 10,841 first-ever ischaemic stroke admissions 
between Jan 2003 and Dec 2016 were initially extracted 
from the NNSTR. Patients with missing follow-up data 
(n = 81), those with missing discharge data (n = 221) 
and those aged under 45 (n = 175) were excluded due to 
the likely different underlying mechanisms of disease in 
younger patients. Therefore, a total of 10,366 ischaemic 
stroke patients aged 45 years and over were included in the 
analysis (Supplementary Fig. 1).
Table 1 presents summary characteristics on admission 
for the entire cohort. Mean age was 78.5 years (standard 
deviation 10.9 years). There were 5409 females (52%). A 
total of 3534 (38.0%) patients suffered a Partial Anterior 
Circulation Stroke (PACS), 2401 (25.8%) of them had a 
Lacunar Stroke (LACS), 1830 (19.7%) patients had a Total 
Anterior Circulation Stroke (TACS) and 1533 (16.5%) 
patients had a Posterior Circulation Stroke (POCS). A total 
of 2916 patients (28.1%) suffered from coronary heart dis-
ease and 6377 (61.5%) from hypertension. Heart failure 
was diagnosed in 1481 (14.3%) patients, atrial fibrillation 
in 3393 (32.7%) patients, cancers in 1660 (16.0%) patients, 
liver disease in 156 (1.5%) patients and peripheral vascu-
lar disease in 437 (4.2%) patients. Over the 10 years of 
follow-up, 4879 patients died (47.1%). Baseline 10-year 
survival was 44%. Median (95% CI) follow-up was 5.47 
(5.35–5.58) years.
Missing data
The following six candidate predictors had missing data 
(ranging from 2.2 to 10.3%): OCSP stroke classification 
(10.3%), pre-stroke modified Rankin score (5.9%), haemo-
globin (4.9%), white blood cell count (2.2%), sodium (2.6%), 
and creatinine (2.5%). Supplementary Tables 2–7 detail the 
characteristics of the included cohort, stratified by whether 
each variable in question had missing data. Patients with 
liver disease, patients without hypertension, as well as older 
patients were more likely to have missing data.
CRP, cholesterol and serum glucose were not included in 
the model since they were missing for a high proportion of 
patients (17.16%, 36.1%, and 24.19%, respectively).
Cox proportional‑hazards model
Candidate predictors included in the final Cox proportional 
hazards model were age [10], sex [10], pre-stroke disability 
(measured using the modified Rankin Score), type of stroke 
[11], haemoglobin [12], sodium [13], white blood cell count 
[14], ischaemic heart disease [10], atrial fibrillation [9], can-
cers [15], hypertension [16], chronic obstructive pulmonary 
Table 1  Patient characteristics
SD standard deviation, IQR inter-quartile range, OCSP oxfordshire 
community stroke project, eGFR estimated glomerular filtration rate, 
PACS partial anterior circulation stroke, LACS lacunar circulation 




Age, mean (SD) 78.4 (10.9)
10-year mortality, N (%) 4879 (47.1)
Haemoglobin, mean (SD) 134.4 (19.6)
WBC, median (IQR) 8.8 (7.1–11.3)
Creatinine, mean (SD) 1.1(0.5)
eGFR, N (%)





  > 90 1102 (10.9)
Sodium, median (IQR) 139 (136–141)
Sex
 Male, N (%) 4957 (47.8)
 Female, N (%) 5409 (52.2)
OCSP classification
 PACS, N (%) 3534 (38.0)
 LACS, N (%) 2401 (25.8)
 TACS, N (%) 1830 (19.7)
 POCS, N (%) 1533 (16.5)
Modified Rankin Scale (on admission)
 0, N (%) 6085 (62.4)
 1, N (%) 1250 (12.8)
 2, N (%) 835 (8.6)
 3, N (%) 942 (9.7)
 4, N (%) 453 (4.6)
 5, N (%) 193 (2.0)
Coronary heart disease, N (%) 2916 (28.1)
Heart failure, N (%) 1481 (14.3)
Atrial fibrillation, N (%) 3393 (32.7)
Cancers, N (%) 1660 (16.0)
Hypertension, N (%) 6377 (61.5)
Liver disease, N (%) 156 (1.5)
Peripheral vascular disease, N (%) 437 (4.2)
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disease [17], liver disease [18], peripheral vascular disease 
[19], heart failure [20, 21] and eGFR [22]. Diabetes was the 
only candidate predictor that was excluded from the final 
model.
Table 2 details the association between each predictor 
and mortality within 10 years as hazard ratios and param-
eter estimates from the Cox proportional-hazards model. The 
baseline survival at 10 years was 0.44. Patients with TACS 
were almost 3 times more likely to die compared those with 
LACS, hazard ratio (95% confidence interval) (HR, 95% CI): 
(2.87, 2.62–3.14). Those with eGFR below 15 were almost 
twice more likely to die after stroke compared to those with 
eGFR over 90 (1.97, 1.55–2.52). Out of all the comorbidities 
included, liver disease had the strongest effect on stroke mor-
tality, with a hazard ratio of (1.50, 1.20–1.87). Hypertension 
was inversely associated with 10-year mortality HR: (0.77, 
0.72–0.82). A 1-year increase in age was associated with 
a 4% increased hazard of mortality HR: (1.04, 1.04–1.05). 
Hazard ratios for haemoglobin, sodium and white blood cell 
count values were computed using RCSs and are shown in 
Supplementary Fig. 2.
Internal validation
The R-squared for the model was 0.32 whilst the C-statistic 
was 0.76 which is recognised as ‘fair’ discrimination abil-
ity [33]. After internal validation, the optimism-adjusted 
R-squared slightly reduced to 0.31 whilst the C-statistic 
remained the same. The calibration slope was 0.98 indicat-
ing good model fit. The relationship between the predicted 
and observed probabilities was also assessed visually using 
a calibration plot and showed good agreement (Fig. 1). The 
blue line on the plot represents the bootstrap bias-corrected 
calibration curve and displays evidence of slight overpredic-
tion for good prognosis patients. However, for poor prog-
nosis patients (survival < 40%), the model appears to be 
accurate.
Figure 2 details the resulting score nomogram based 
on the results of the Cox proportional-hazards model. For 
example, a female 60-year-old patient with haemoglobin 
level of 120, sodium of 135, white blood count of 6.5, eGFR 
of 45, with pre-stroke modified Rankin score of 1 and his-
tory of AF and no other comorbidities, who suffered a partial 
anterior circulation stroke, would receive 71.66 points. This 
corresponds to 10-year survival of 0.74.
Supplementary Fig. 4 details the distribution of the total 
score points across the study population, calculated using the 
provided nomogram. The total score points were normally 
distributed across the study population with mean (SD): 113 
(38.6), Min = 11.54 and Max = 250.36.
Supplementary Fig.  5 details the observed 10-year 
survival curves, stratified by score quintiles (Fifth 1: 
11.5–79.5, Fifth 2: 79.4, 100.9, Fifth 3: 100.9–120.9, Fifth 
4:120.9–145.8, Fifth 5: 145.8–250.4). The score discrimi-
nates well between strata according to their risk of death 
within 10 years.
Discussion
To the best of our knowledge, this is the first study to 
develop and internally validate a nomogram to predict 
10-year mortality using point of care data for patients with 
an ischaemic stroke. Using a large UK regional registry of 
consecutive stroke admissions with long-term post-discharge 
follow-up data, we developed a prediction model that uses 
co-morbidities, laboratory results as well as age and sex of 
the patients and stroke type. Our score, presented as a nomo-
gram for clinical use, is a simple tool that can be used to 
predict long-term patient mortality and includes only rou-
tinely collected variables during initial routine work-up on 
acute stroke admissions, rendering them available in most 
healthcare facilities. It has numerous applications in prac-
tice, including informing discussions and planning with the 
patient and families and providing the prognosis for patients. 
Additionally, future studies can use the score as a benchmark 
for interventions.
Numerous stroke mortality scores have been previously 
developed. Outcomes considered in such scores include 
mortality and recurrence, as well as functional outcomes 
measured by mRS (modified Rankin Score) and length-of-
stay in the hospital. They have been analysed and compared 
in several reviews [4–6]. However, so far, none of them pre-
dicts mortality as far as 10 years post-stroke. Furthermore, 
none of them is commonly used in clinical practice. One 
of the possible reasons is the complexity of calculating the 
scores either due to complicated formulae or incorporating 
the neuroimaging results. Furthermore, some of the scores 
require specialist knowledge, which can make them less 
likely to be used by general clinicians.
Whilst research into 10-year ischaemic stroke mortal-
ity predictors is limited due to most studies lacking such 
long follow-up, it has been previously shown that predic-
tors of short- and long-term stroke mortality predictors 
can differ [34]. The difference is particularly visible when 
comorbidities and variables associated with atherosclerotic 
vascular disease are considered (such as peripheral artery 
disease), as they seem to predict long-term, but not short-
term mortality [34]. Most prediction models for short-term 
ischaemic stroke mortality focus on acute baseline details 
such as glucose levels on admission, time from onset to pres-
entation, GCS (Glasgow Coma Scale), level of conscious-
ness and stroke subtype [35]. While some of these factors 
may predict long-term outcomes, longer term prediction 
models rely more heavily on comorbid conditions [34]. 
In our score, candidate predictors such as ischaemic heart 
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Table 2  Results of the 
multivariable Cox proportional-
hazards model of 10-year stroke 
mortality
HR hazard ratio, OCSP oxfordshire community stroke project, eGFR estimated glomerular filtration rate, 
PACS partial anterior circulation stroke, LACS Lacunar Circulation Stroke, TACS total anterior circulation 
stroke, POCS posterior circulation stroke, RCS restricted cubic spline
a Variables were presented as restricted cubic splines (see Supplementary Fig. 2). See “Results” for hazard 
ratios at different values of these predictors. Baseline survival was 44%
Variable HR (95% CI) Log HR (95% CI)
Age 1.04 (1.04, 1.05) 0.042 (0.039, 0.046)
Sex (F:M) 0.87 (0.82,0.93) − 0.140 (− 0.202, − 0.077)
OCSP classification
 LACS Reference Reference
 PACS 1.20 (1.10, 1.30) 0.182 (0.099, 0.265)
 TACS 2.87 (2.62, 3.14) 1.055 (0.965, 1.145)
 POCS 1.29 (1.16, 1.44) 0.257 (0.152, 0.362)
eGFR
  <  = 15 1.97 (1.55, 2.52) 0.680 (0.438, 0.923)
 15–30 1.61 (1.36, 1.91) 0.475 (0.304, 0.646)
 30–45 1.34 (1.15, 1.57) 0.294 (0.138, 0.451)
 45–60 1.12 (0.96, 1.30) 0.110 (− 0.041, 0.261)
 60–90 1.04 (0.91, 1.20) 0.043 (− 0.098, 0.184)
  > 90 Reference Reference
Modified Rankin Scale (on admission) 1.20(1.17, 1.22) 0.181 (0.160, 0.202)
Atrial fibrillation 1.17 (1.10, 1.24) 0.153 (0.092, 0.214)
Coronary heart disease 1.09 (1.02, 1.16) 0.083 (0.018, 0.148)
Congestive heart failure 1.24 (1.15, 1.34) 0.216 (0.138, 0.295)
Cancers 1.37 (1.27, 1.47) 0.312 (0.239, 0.385)
Hypertension 0.77 (0.72, 0.82) − 0.262 (− 0.322, − 0.202)
Chronic obstructive pulmonary disease 1.13 (1.03, 1.25) 0.125 (0.025, 0.225)
Liver disease 1.50 (1.20, 1.87) 0.405 (0.184, 0.625)
Peripheral vascular disease 1.39 (1.23, 1.57) 0.329 (0.204, 0.454)
Haemoglobin a
 RCS1 − 0.152 (− 0.183, 0.886)
 RCS2 − 0.056 (− 0.085, 0.973)
 RCS3 − 0.019 (− 0.046, 1.008)
 RCS4 − 0.029 (− 0.057, 0.998)
 RCS5 − 0.020 (− 0.049, 1.010)
 RCS6 − 0.006 (− 0.037, 1.025)
WBC a
 RCS1 0.013 (− 0.015, 1.042)
 RCS2 − 0.045 (− 0.072, 0.982)
 RCS3 − 0.042 (− 0.069, 0.986)
 RCS4 0.033 (0.005, 1.062)
 RCS5 − 0.009 (− 0.038, 1.020)
Sodium a
 RCS1 0.206 (0.178, 1.265)
 RCS2 0.002 (− 0.025, 1.030)
 RCS3 0.069 (0.042, 1.100)
 RCS4 − 0.021 (− 0.050, 1.008)
 RCS5 − 0.009 (− 0.039, 1.020)
 RCS6 − 0.035 (− 0.063, 0.993)
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disease, atrial fibrillation, cancers, hypertension, COPD, 
liver disease, peripheral vascular disease and heart failure 
were included in the final model.
Stroke mortality was a common outcome predicted by 
previous scores, which included inpatient [35], 7 days [35], 
1 month [36], 3 months [37] 6 months [38], 1 year [36, 
39, 40], 2 years [41] and 5 years [42] mortality. The long-
est term mortality study [43] predicted death at 10 years or 
more, but this study only included patients with Transient 
Ischaemic Attacks or minor strokes. One of the scores with 
similar outcome and patient population (ischaemic stroke) 
is the ASTRAL score [42]. It was initially created to predict 
3 months mortality and was also found to predict mortality 
up to 5 years. The predictors included were age, acute glu-
cose, visual field defect, level of consciousness, time from 
the onset of symptoms and stroke severity (NIHSS). How-
ever, the ASTRAL score requires availability of measure-
ment of the time from stroke onset, which can sometimes 
be difficult to obtain and thus not available in all patients.
A review of acute stroke prediction models [6] such as 
iSCORE, SOAR, PLAN and THRIVE amongst others, con-
cluded that practical aspects of the score can be potentially 
a limiting factor in the clinical usage of the scores, as the 
majority of them have a good predictive accuracy and have 
Fig. 1  Calibration plot—the observed 10-year survival is plotted 
against the predicted 10-year survival in groups of 500 patients. The 
black line is the calibration in the original dataset estimated by hazard 
regression. The blue line is the optimism-corrected hazard regression 
smoothed curves. The gray line is a reference line representing per-
fect calibration
Fig. 2  Nomogram. A nomo-
gram is a tool used for calculat-
ing probabilities in predictive 
models using a visual rep-
resentation. The nomogram 
was created based on the Cox 
proportional-hazards model 
coefficients (Table 2 and 
Supplementary Fig. 2). Each 
variable value is represented on 
a separate axis. Each variable’s 
value should be found on the 
variable axis, then the amount 
of corresponding points should 
be noted from the ‘Points’ axis. 
The total of all these scores 
(Total Point axis) can then be 
used to determine the predicted 
10-year mortality (10-year 
Mortality axis)
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been externally validated. Data unavailability and limited 
resources can be a potential obstacle in wider adoption of 
these scores, which can be the case with some of the models 
including biomarkers [44] or those using imaging data [45].
Our score and nomogram have numerous strengths. This 
10-year ischaemic stroke score provides quick way for clini-
cians to estimate predicted survival of their patients at the 
time of stroke presentation. Such information can be useful 
in several circumstances, including in making appropriate 
decisions regarding secondary prevention and facilitating 
discussions with patients and their relatives/carers. Fur-
thermore, understanding long-term survival in this patient 
population is relevant and pertinent to health care planning 
and policy. It has been developed on a large sample (10,366 
patients) with robust ascertainment of co-morbidities and 
follow-up data through data linkage with the UK National 
Health Service system [9]. Furthermore, it only contains 
data available on admission and does not require any special-
ist investigations. Visualisation of the score in a form of a 
nomogram increases the potential of uptake in clinical prac-
tice especially in conjunction with future CV risk prediction 
scores and can help clinicians to risk stratify for appropriate 
intervention strategies. It does not require stroke specialist 
knowledge, which makes it more generally useful for other 
healthcare professionals.
We also acknowledge certain limitations. The inverse 
association between hypertension and 10-year mortality in 
our model was unexpected. This is likely to be driven by 
residual confounders, such as anti-hypertensive treatment, 
data on which were unavailable in our registry. Another fac-
tor affecting this association may be stroke severity. The 
NIHSS scale recorded in our database had a high propor-
tion of missing values and could not be incorporated in the 
model. However, we utilised the OCSP stroke classification 
as a proxy for stroke severity [46]. Further research should 
assess whether the addition of treatment data and NIHSS to 
our score would increase the predictive ability of the score 
using. We were unable to adjust for treatment effect but it 
is complex and unrealistic to fully account for this given 
treatment variation over time. The same principle applies 
with regard to stroke severity (NIHSS), some relevant blood 
results (glucose, cholesterol and C-reactive protein) and 
severity of comorbidities. External validation on a differ-
ent dataset is also needed to assess its generalisability in a 
global setting.
Conclusion
In conclusion, we have developed the first 10-year stroke 
mortality score, taking into account a wide range of comor-
bid factors and blood parameters available on admission. 
We also provide a nomogram to facilitate application at the 
point of care. Further external validation on an independ-
ent dataset is required to ensure generalisation to different 
ethnicities and healthcare settings.
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